NeuPath Health Inc. (TSXV:NPTH)
0.5700
0.00 (0.00%)
Aug 21, 2026, 3:54 PM EST
NeuPath Health Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, NeuPath Health stock has a consensus rating of "Buy" and an average price target of $0.77. The average 1-year stock price forecast is 35.09% higher than the current stock price, while the lowest is $0.58 (+1.75%) and the highest is $0.95 (+66.67%).
Price Target: $0.77 (+35.09%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Mar 27, 2026.
Analyst Ratings
The average analyst rating for NeuPath Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Nov '25 | Mar '26 | Apr '26 | May '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $0.58 | Buy | Maintains | $0.58 | +1.75% | Mar 27, 2026 |
Financial Forecast
Revenue This Year
93.50M
from 87.19M
Increased by 7.23%
Revenue Next Year
102.80M
from 93.50M
Increased by 9.95%
EPS This Year
0.08
EPS Next Year
0.10
from 0.08
Increased by 25.00%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.